Due to unprecedented growth since the practice's inception, Behavioral Pediatrics of Rural Georgia has a new home to accommodate the needs of neurodivergent families in Bulloch County and beyond. The ...

As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYStm (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This ...

Zevra Therapeutics, Inc. ( NASDAQ: ZVRA) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President and CEO LaDuane ...

There are many resources to support parents of children with developmental disabilities, and help them to understand their ...

Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, ...

What started as a student with a promising future, turned to a patient barely able to move on her own. It only took a split ...

A play date turned into a nightmare for Avery Russell, 11, when pit bulls attacked and nearly killed her. Now her family ...

It’s very easy to find the ugly in the last few months. But if you look beyond the ugly, there’s so many beautiful moments.” ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses the promising results of DB-OTO in the CHORD trial for children with otoferlin-related hearing loss.

As a measles outbreak in West Texas grows, the response from U.S. Health and Human Services Secretary Robert F. Kennedy Jr.

The review also evaluates emerging personalized approaches such as gene and mRNA therapy that hold promise for restoring ciliary function and reducing the burden of acute infections in pediatric PCD.